A Phase II Study of Pazopanib GW786034, NSC 737754 in Children, Adolescents and Young Adults With Refractory Solid Tumors

Trial Profile

A Phase II Study of Pazopanib GW786034, NSC 737754 in Children, Adolescents and Young Adults With Refractory Solid Tumors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Ewing's sarcoma; Liver cancer; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 13 Jan 2017 Time frame of primary endpoint has changed from up to 24 cycles from the start of treatment to Primary analysis perform 20 weeks after LPFV in the 3 cohorts of primary interest
    • 08 Aug 2016 Planned End Date changed from 1 Aug 2019 to 1 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top